Eli Lilly and Co
LLY
Eli Lilly and Co News & Analysis
stocks
Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure
We’ve raised our fair value estimate of Lilly stock.
stocks
A wave of US biotech IPOs may be starting - here’s why
M&A activity is bolstering IPOs within key areas of the biotech space. A GLP-1 maker and a protein biomarker detection company are the latest.
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,218.24 | 26.05 | -0.32% |
| DAX 40 | 24,759.05 | 185.90 | -0.75% |
| Dow JONES (US) | 50,866.78 | 695.15 | -1.35% |
| FTSE 100 | 10,368.05 | 7.73 | 0.07% |
| HKSE | 24,961.95 | 291.45 | -1.15% |
| NASDAQ | 25,709.43 | 1,121.53 | -4.18% |
| Nikkei 225 | 66,588.12 | 882.57 | -1.31% |
| NZX 50 Index | 13,161.97 | 60.36 | 0.46% |
| S&P 500 | 7,383.74 | 200.57 | -2.64% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 4,027.74 | 30.04 | -0.74% |